1. A less-than-Valeant effort?

Discounted prices are coming for Valeant’s Nitropress and Isuprel. However, rebates “of at least 10%” on the heels of price hikes of 525% and 212% this past year are leaving the U.S. Congress unimpressed. Rep. Elijah Cummings (D-MD), who’s been calling for more regulation on drug pricing, commented, “This is a small step in the right direction, but it comes nowhere close to fully addressing this critical problem.” Cummings’ concern is that patients take the brunt of “massive price increases” all in the name of company profits. Valeant CEO Joseph Papa announced that they made mistakes and are “committed to getting it right” when it comes to the pricing issue. But you have to wonder if they gave any thought to the timing of these bonuses. Yikes.